Icecure Medical (ICCM) has released an update.
IceCure Medical’s latest European study, published in the journal ‘Cancers’, showcases the safety and efficacy of its ProSense® Cryoablation System for treating metastatic and recurrent breast cancer, with a notably low complication rate and high success in tumor ablation. Highlighting the minimally invasive nature of the treatment, the study reports a 100% initial complete ablation rate and encouraging survival rates in a diverse high-risk patient group. These findings bolster ProSense® as a viable treatment option for a broad spectrum of breast cancer cases, extending its applicability beyond early-stage disease.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
